TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.45 USD
-0.04 (-2.68%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 5:52 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 61 - 70 ( 70 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Another Validation for TRC105, Data from Four Phase 2''s Coming Up
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Entry Point Ahead of Data Deluge
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Intriguing Play in the $16B Global Anti-VEGF Market-Initiate with Buy rating and $18 target
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D